Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Trial Profile

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Gastric cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 16 Nov 2018 Results evaluating whether high MET mutant Allele Frequency of METex14 predicts tumor response to glesatinib from 265-109 and 265-101, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 02 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 26 Feb 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top